Showing results (421-430 of 487) with videos related to

Sort By:
Pageof 49
International Journal of Radiation Oncology, Biology, Physics|October 24, 2025
Commissioning, Characterization, and First High-Dose-Rate Irradiations at a Compact X-Ray Tube for Microbeam and Minibeam Radiation TherapyChristian Petrich, Johanna Winter, Anton Dimroth, et al.
Cancers|June 2, 2021
Long-Term Outcome of Neoadjuvant Tyrosine Kinase Inhibitors Followed by Complete Surgery in Locally Advanced Dermatofibrosarcoma ProtuberansJessica Beaziz, Maxime Battistella, Julie Delyon, et al.
Medical Physics|March 22, 2022
Heat management of a compact x-ray source for microbeam radiotherapy and FLASH treatmentsJohanna Winter, Anton Dimroth, Sebastian Roetzer, et al.
The Journal of General Virology|February 12, 2026
Remodelling of P-bodies and the cytoskeleton by <i>Orthohantavirus puumalaense</i> (Puumala virus)Hannah Sabeth Schwarzer-Sperber, Annette Petrich, Matthias Schade, et al.
Leukemia & Lymphoma|May 31, 2012
Outcome of patients with relapsed/refractory acquired immune deficiency syndrome-related lymphoma diagnosed 1999-2008 and treated with curative intent in the AIDS Malignancy ConsortiumUlas D Bayraktar, Juan Carlos Ramos, Adam Petrich, et al.
Frontiers in Immunology|March 15, 2024
Directing the migration of serum-free, <i>ex vivo</i>-expanded Vγ9Vδ2 T cellsKiran K Parwani, Gianna M Branella, Rebecca E Burnham, et al.
Journal of Virology|May 1, 2020
Macropinocytosis and Clathrin-Dependent Endocytosis Play Pivotal Roles for the Infectious Entry of Puumala VirusSandy Bauherr, Filip Larsberg, Annett Petrich, et al.
Antiviral Research|February 13, 2025
Antiviral mechanisms and preclinical evaluation of amantadine analogs that continue to inhibit influenza A viruses with M2<sup>S31N</sup>-based drug resistanceIan Tietjen, Daniel C Kwan, Annett Petrich, et al.
Journal of Lower Genital Tract Disease|August 3, 2016
Observational Management of CIN 2 in Young Women: A Prospective Multicenter TrialPeter Sykes, Carrie Innes, Dianne Harker, et al.
Leukemia & Lymphoma|August 2, 2021
A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV + lymphomasWilliam B Pearse, Adam M Petrich, Leo I Gordon, et al.
Pageof 49